Critical Reviews in Oncology / Hematology
Volume 74 , Pages S11-S15 , April 2010

Routine adjuvant use of bisphosphonates in breast cancer Arguments in favour and against

  • Ingo Diel

      Affiliations

    • Center for Gynecological Oncology, Mannheim, Germany
    • Corresponding Author InformationCorresponding authors. Ingo Diel, MD. Professor of Gynecology and Obstetrics, Center for Gynecological Oncology, Quadrat P 7, 16–18, 68161 Mannheim, Germany
    • ,
  • Stefan Aebi

      Affiliations

    • Breast and Gynecologic Cancer Center, Departments of Gynecology and Medical Oncology, University Hospital, Berne, Switzerland
    • Corresponding Author InformationStefan Aebi, MD. Associate Professor of Medical Oncology, University of Berne, Switzerland

References 

  1. Zheng Y , Zhou H , Fong-Yee C , et al.   Bone resorption increases tumor growth in a mouse model of osteosclerotic breast cancer metastasis . Clin Exp Metastasis . 2008;25:559–567
  2. Zheng Y , Zhou H , Modzelewski JR , et al.   Accelerated bone resorption due to dietary calcium deficiency promotes breast cancer tumor growth in bone . Cancer Res . 2007;67:9542–9548
  3. Zheng Y , Zhou H , Brennan K , et al.   Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis . Bone . 2007;40:471–478
  4. Krempien B , Diel I , Jöckle-Kretz B , et al.   The Walker Carcinosarcoma 256 model for the development of bone metastases. Influence of skeletal metabolism on the development of bone metastases . Verh Dtsch Ges Path . 1984;68:211–216
  5. Senaratne SG , Prianov G , Mansi JL , et al.   Bisphosphonates induce apoptosis in human breast cancer cell lines . Br J Cancer . 2000;82:1459–1468
  6. Jagdev SP , Coleman RE , Shipman CM , et al.   The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells; evidence for synergy with paclitaxel . Br J Cancer . 2001;84:1126–1134
  7. Boissier S , Ferreras M , Peyruchaud O , et al.   Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases . Cancer Res . 2000;60:2949–2954
  8. Daubiné F , Le Gall C , Gasser J , Green J , Clézardin P . Antitumor effects of clinical dosis regimens of bisphosphonates in experimental breast cancer bone metastasis . J Natl Cancer Inst . 2007;99:322–330
  9. Diel IJ , Solomayer EF , Costa SD , et al.   Reduction in new metastases in breast cancer with adjuvant clodronate treatment . N Engl J Med . 1998;339:357–363
  10. Diel IJ . Bisphosphonates in the prevention of bone metastases: current evidence . Semin Oncol . 2001;28(11):75–80
  11. Diel IJ , Jaschke A , Solomayer EF , et al.   Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long term follow-up . Ann Oncol . 2008;19:2007–2011
  12. Saarto T , Blomqvist C , Virkkunen P , Elomaa I . Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial . J Clin Oncol . 2001;19:10–17
  13. Saarto T , Vehmanen L , Virkkunen P , Blomqvist C . Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients . Acta Oncol . 2004;43:650–656
  14. Powles T , Paterson S , Kanis JA , et al.   Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer . J Clin Oncol . 2002;20:3219–3224
  15. Powles T , Paterson A , McCloskey E , et al.   Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] . Breast Cancer Res . 2006;8:R13
  16. Gnant M , Mlineritsch B , Schippinger W , et al.   Endocrine therapy plus zoledronic acid in premenopausal breast cancer . N Engl J Med . 2009;360:679–691
  17. Eidtmann H , Bundred NJ , DeBoer R , et al.   The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST . Cancer Res . 2009;69(Suppl 2):74S; [abstract 44].
  18. Winter MC , Thorpe HC , Burkinshaw R . The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumour activity in breast cancer . Cancer Res . 2009;69(Suppl 2):5101; [abstract].
  19. Pavlakis N , Schmidt R , Stockler M . Bisphosphonates for breast cancer . Cochrane Database Syst Rev . 2005; CD003474.
  20. Bundred NJ , Campbell ID , Davidson N , et al.   Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results . Cancer . 2008;112:1001–1010
  21. Gnant M , Mlineritsch B , Schippinger W , et al.   Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12 . J Clin Oncol . 2008;26(Suppl 15S, Pt II):1006S

PII: S1040-8428(10)70005-6

doi: 10.1016/S1040-8428(10)70005-6

Critical Reviews in Oncology / Hematology
Volume 74 , Pages S11-S15 , April 2010

Article Tools